Drug-Resistant Tuberculosis in High-Risk Groups, Zimbabwe

To estimate prevalence of multidrug-resistant tuberculosis (MDR TB) in Harare, Zimbabwe, in 2012, we performed microbiologic testing on acid-fast bacilli smear-positive sputum samples from patients previously treated for TB. Twenty (24%) of 84 specimens were consistent with MDR TB. A national drug-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Metcalfe, John Z., Makumbirofa, Salome, Makamure, Beauty, Sandy, Charles, Bara, Wilbert, Mungofa, Stanley, Hopewell, Philip C., Mason, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2014
Materias:
Dispatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884722/
https://www.ncbi.nlm.nih.gov/pubmed/24377879
http://dx.doi.org/10.3201/eid2001.130732
_version_ 1782298635379146752
author Metcalfe, John Z.
Makumbirofa, Salome
Makamure, Beauty
Sandy, Charles
Bara, Wilbert
Mungofa, Stanley
Hopewell, Philip C.
Mason, Peter
author_facet Metcalfe, John Z.
Makumbirofa, Salome
Makamure, Beauty
Sandy, Charles
Bara, Wilbert
Mungofa, Stanley
Hopewell, Philip C.
Mason, Peter
author_sort Metcalfe, John Z.
collection PubMed
description To estimate prevalence of multidrug-resistant tuberculosis (MDR TB) in Harare, Zimbabwe, in 2012, we performed microbiologic testing on acid-fast bacilli smear-positive sputum samples from patients previously treated for TB. Twenty (24%) of 84 specimens were consistent with MDR TB. A national drug-resistance survey is needed to determine MDR TB prevalence in Zimbabwe.
format Online
Article
Text
id pubmed-3884722
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-38847222014-01-08 Drug-Resistant Tuberculosis in High-Risk Groups, Zimbabwe Metcalfe, John Z. Makumbirofa, Salome Makamure, Beauty Sandy, Charles Bara, Wilbert Mungofa, Stanley Hopewell, Philip C. Mason, Peter Emerg Infect Dis Dispatch To estimate prevalence of multidrug-resistant tuberculosis (MDR TB) in Harare, Zimbabwe, in 2012, we performed microbiologic testing on acid-fast bacilli smear-positive sputum samples from patients previously treated for TB. Twenty (24%) of 84 specimens were consistent with MDR TB. A national drug-resistance survey is needed to determine MDR TB prevalence in Zimbabwe. Centers for Disease Control and Prevention 2014-01 /pmc/articles/PMC3884722/ /pubmed/24377879 http://dx.doi.org/10.3201/eid2001.130732 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Dispatch
Metcalfe, John Z.
Makumbirofa, Salome
Makamure, Beauty
Sandy, Charles
Bara, Wilbert
Mungofa, Stanley
Hopewell, Philip C.
Mason, Peter
Drug-Resistant Tuberculosis in High-Risk Groups, Zimbabwe
title Drug-Resistant Tuberculosis in High-Risk Groups, Zimbabwe
title_full Drug-Resistant Tuberculosis in High-Risk Groups, Zimbabwe
title_fullStr Drug-Resistant Tuberculosis in High-Risk Groups, Zimbabwe
title_full_unstemmed Drug-Resistant Tuberculosis in High-Risk Groups, Zimbabwe
title_short Drug-Resistant Tuberculosis in High-Risk Groups, Zimbabwe
title_sort drug-resistant tuberculosis in high-risk groups, zimbabwe
topic Dispatch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884722/
https://www.ncbi.nlm.nih.gov/pubmed/24377879
http://dx.doi.org/10.3201/eid2001.130732
work_keys_str_mv AT metcalfejohnz drugresistanttuberculosisinhighriskgroupszimbabwe
AT makumbirofasalome drugresistanttuberculosisinhighriskgroupszimbabwe
AT makamurebeauty drugresistanttuberculosisinhighriskgroupszimbabwe
AT sandycharles drugresistanttuberculosisinhighriskgroupszimbabwe
AT barawilbert drugresistanttuberculosisinhighriskgroupszimbabwe
AT mungofastanley drugresistanttuberculosisinhighriskgroupszimbabwe
AT hopewellphilipc drugresistanttuberculosisinhighriskgroupszimbabwe
AT masonpeter drugresistanttuberculosisinhighriskgroupszimbabwe

Ejemplares similares